Member of Lyonbiopole
Advanced BioDesign, a clinical-stage pharmaceutical company specializing in the development of new therapeutic approaches to resistant cancers,
Through ODYSSEY, its first in human trial evaluating the tolerability of ABD-3001, a first-in-class ALDH1 inhibitor, in monotherapy in relapse/refractory Acute Myeloid Leukemia (AML) patients resistant to standard therapies.
Strategic application domain: Human Medicine
Application market: Oncology
Type of activity: CRO - Tools - R&D platform, Diagnostics, Therapeutics, Pharma or Biotech
Technologies: Molecular Biology & Nucleic acid, Small Molecules
Created on aug. 2nd, 2010 - 16 employees
Address
Parc Technologique de Lyon - 655, Allée des Parcs - Bâtiment D - 69800 Saint Priest - France 69800 St Priest
Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.